Ann Rheum Dis: Adamu mono-resistance reduction in patients with long-term clinical remission of rheumatoid arthritis

The study was designed to explore a link between baseline disease activity in patients with persistently remission of rheumatoid arthritis (RA) and the reduction of Adamu monoantigens or acute seizures after discontinuationPhase IV, randomized, double-blind (DB) PREDICTRA study (the effect of residual inflammation, drug levels and patient characteristics on Adamu mono-destoonant outcomes detected by imaging techniques) was included in the continued remission of RA patients who received Adamu monoantigen 40 mg every 1 weekAfter a 4-week open label introduction period (OL-LI), patients were randomly divided into DB Adamu mono-resistance group (every 3 weeks) or discontinued group (placebo) at a 5:1 ratio for a total of 36 weeksThe main endpoint is the link between inflammation detected by DB baseline hand and wrist MRI and acute seizures122 of the 146 patients treated during OL-LI were randomly assigned to the subtraction group (n?102) or the discontinued group (n-20)The average duration of active diseases in patients was 12.9 years, and the average duration of treatment for Adamu monoantigen was 5.4 years (an average of 2.2 years of continuous remission)Overall, 37 (36%) and 9 (45%) of the reduced and discontinued groups had acute seizures (18.0 weeks and 13.3 weeks of acute seizures)Both DB baseline disease characteristics and Adamu monoantigen concentrations were not associated with acute seizures after Adamu mono-resistance reductionAfter 16 weeks of open label Adamu mono-resuscitation treatment, about half of acute seizure patients recovered from clinical remissionSecurity is consistent with past researchabout one-third of Adamu mono-destoonated patients and one-half of patients with out-of-the-heart within 36 weeks had an acute attackThe time of acute seizure in the subtraction group was numerically higher than that of the discontinuation groupBaseline MRI inflammation is not associated with seizures